Company Overview and News

 
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers

2018-05-03 globenewswire
NANOBIOTIX PARTNERS WITH WEILL CORNELL MEDICINE ON PRE-CLINICAL STUDIES TO EVALUATE THE IMPACT OF NBTXR3 ON cGAS-STING PATHWAY IN MAMMARY CANCERS

 
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway

2018-04-17 globenewswire
AACR ANNUAL MEETING 2018: NANOBIOTIX PRESENTED PRECLINICAL DATA SHOWING NBTXR3 NANOPARTICLES CAN ACTIVATE THE cGAS-STING PATHWAY

 
NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB

2018-04-10 globenewswire
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB

 
NANOBIOTIX : Nanobiotix 2017 Annual Results

2018-03-30 globenewswire
Paris, France and Cambridge, Massachusetts, USA, March 30, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2017:

 
Nanobiotix set for important 2017 as cancer therapy trials advance

2016-11-29 proactiveinvestors.com.au
It promises to be significant year for Nanobiotix SA (EPA:NANO) in 2017 as the French cancer-focussed biotech developer closes in on a green-light for its lead product in Europe.

 
Nanobitix set for important 2017 as cancer therapy trials advance

2016-11-29 proactiveinvestors.com.au
It promises to be significant year for Nanobiotix SA (EPA:NANO) in 2017 as the French cancer-focussed biotech developer closes in on a green-light for its lead product in Europe.

 
Nanometrics (NANO) Looks Good: Stock Up 6.5% in Session

2016-06-22 zacks
Nanometrics Incorporated (NANO - Snapshot Report) was a big mover last session, as the company saw its shares rise over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $17.90 to $19.24 in the past one-month time frame. The company has seen no estimate revisions over the past 30 days, while the Zacks Consensus Estimate remained unchanged over the same time frame.

 
7 Stocks with Recent Price Strength to Boost Your Returns

2016-06-02 zacks
In the stock market, finding a win-win strategy is easier said than done. In the current highly volatile market, it is difficult for even an ardent investor to come up with a foolproof approach.

 
Add These 5 Stocks with Recent Price Strength to Your Portfolio

2016-05-17 zacks
An investor always seeks a win-win strategy. While this sounds like a simple task, it is easier said than done.In the current highly volatile market, it is difficult for even an ardent investor to come up with a foolproof approach.

 
The Zacks Analyst Blog Highlights: Daqo New Energy, BioTelemetry, Ebix, Primo Water and Nanometrics

2016-05-02 zacks
Chicago, IL – May 02, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Daqo New Energy Corp. ((DQ - Snapshot Report)), BioTelemetry, Inc. ((BEAT - Snapshot Report)), Ebix Inc. ((EBIX - Snapshot Report)), Primo Water Corp.

 
5 Stocks with Recent Price Strength to Buy Now

2016-04-29 zacks
An investor always seeks a win-win strategy, but in the current highly volatile market, it is difficult for even an ardent investor to come up with a foolproof approach. When it comes to stock investing, people generally look for beaten down stocksthat have the potential to recover faster than others. But this also bears the risk of disappointment. Particularly, one could fall prey to value trap if fails to identify the hidden weakness in the selected stock.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

8h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

8h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

18h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...